|drug2933||SARS-CoV-2 serological assessment (IgG) Wiki||0.71|
|drug899||Convalescent plasma Wiki||0.15|
|D045169||Severe Acute Respiratory Syndrome NIH||0.06|
|D003141||Communicable Diseases NIH||0.05|
|D018352||Coronavirus Infections NIH||0.05|
There are 2 clinical trials
This study is a interventional study that present minimal risks and constraints to evaluate the presence of novel coronavirus (SARS-CoV-2) or antibodies among individuals living in households where there is a confirmed coronavirus case in order to provide useful information on the proportion of symptomatic forms and the extent of the virus transmission in tropical regions such as French Guiana, Guadeloupe and New-Caledonia.
Description: The extent of the virus transmission within households will be assessed by evaluating the rate of intra-household secondary transmission of the virusMeasure: Evaluation of the extent of the virus transmission within households Time: 2 years
Description: The characterization of the secondary cases will be assessed by evaluating the proportion of asymptomatic forms within the householdMeasure: Characterization of the secondary cases Time: 2 years
Description: The characterization of the secondary cases will be assessed by characterizing the risk factors for coronavirus infection.Measure: Characterization of the secondary cases Time: 2 years
Description: The extent of the virus transmission within contact persons will be assessed by evaluating the rate of extended-contact secondary transmission of the virusMeasure: In New-Caledonia, evaluation of the extent of the virus transmission within contact persons Time: 2 years
An initial retrospective epidemiological investigation was conducted in a city north of France after the diagnosis of the first case of COVID-19 on February 2020. Sero-epidemiological studies were conducted in this town by the Institut Pasteur in early 2020 among families, teachers and non-teaching staff of the high and elementary schools. The goal of this new project is to better characterize the specific immunity generated by the infection within this community. The specific immune response to the SARS-CoV-2 virus will be followed for a period of 2 years from the initial circulation of the virus, within a large cohort of participants covering all age groups from 5 years-old onwards. The study will focus on systemic humoral and cell responses, immunity of the nasopharyngeal mucosa and the humoral response present in saliva. Follow-up of participants in this cohort and monitoring of the virus circulation within this community would help to determine the protective character against re-infection of the natural immunity generated by SARS-CoV-2.
Description: Description of the serological status of individualsMeasure: Presence of specific anti-SARS-CoV-2 antibodies in the different study groups. Time: 2 years
Description: Detection over time the specific T cell response to the SARS-CoV-2 virus.Measure: Presence of specific T cell response to the SARS-CoV-2 Time: 2 years
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports